Claims for Patent: 9,132,118

Summary for Patent: 9,132,118

Title:	Taxane analogs for the treatment of brain cancer
Abstract:	Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
Inventor(s):	McChesney; James D. (Etta, MS), Tapolsky; Gilles (Louisville, KY), Emerson; David L. (Longmont, CO), Marshall; John (Washington, DC), Kurman; Michael (Upper Saddle River, NJ), Modiano; Manuel (Tucson, AZ)
Assignee:	Tapestry Pharmaceuticals, Inc. (Atlanta, GA)
Application Number:	13/785,753
Patent Claims:	1. A compound of the structure of formula (1): ##STR00026## 2. The compound of claim 1, wherein the compound of formula (1) is an isomer having the structure of formula R-(1): ##STR00027## 3. The compound of claim 1, wherein the compound of formula (1) is an isomer having the structure of formula S-(1): ##STR00028## 4. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier. 5. The pharmaceutical composition of claim 4 further comprising one or more chemotherapeutic agents effective in the treatment of brain cancer. 6. The composition of claim 4 which further comprises temozolomide or bevacizumab. 7. The composition of claim 4 formulated for oral administration. 8. The pharmaceutical composition of claim 4, wherein the compound has the structure of formula S-(1): ##STR00029##

Details for Patent 9,132,118

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2027-02-28